UNITED STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date

of report (Date of earliest event reported): October 15, 2009

PFIZER

INC.

(Exact

name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other

jurisdiction of

incorporation)

(Commission File

Number)

(I.R.S. Employer

Identification No.)

235 East 42nd Street

New York, New York

10017

(Zip

Code)

(Address

of principal executive offices)

Registrant s telephone number, including area code:

(212)

573-2323

Not Applicable

(Former Name or Former Address, if

changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to

simultaneously satisfy the obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b))

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c))

Item

2.01. Completion of Acquisition or Disposition of Assets

On October 15, 2009, Pfizer Inc. ( Pfizer ) completed its acquisition of

Wyeth. Pursuant to the Agreement and Plan of Merger, dated as of January

25, 2009, as amended (the Merger Agreement ) among Pfizer, Wyeth and

Wagner Acquisition Corp., a wholly owned subsidiary of Pfizer ( Merger

Sub ), Merger Sub was merged with and into Wyeth (the Merger ). Wyeth

survived the Merger as a wholly owned subsidiary of Pfizer.

As a result of the Merger, each outstanding share of Wyeth common stock,

other than shares directly or indirectly held by Pfizer or Wyeth (which

were canceled as a result of the Merger), shares of restricted stock

(which are entitled to receive cash consideration pursuant to the terms

of the Merger Agreement), and shares with respect to which appraisal

rights were properly executed and not withdrawn, was converted into the

right to receive $33.00 in cash, without interest, and 0.985 of a share

of Pfizer common stock.

The foregoing description of the Merger and the Merger Agreement does

not purport to be complete and is qualified in its entirety by reference

to the Merger Agreement, which is incorporated herein by reference as

Exhibit 2.1.

Attached hereto as Exhibit 99.1 and incorporated herein by reference is

Pfizer's press release dated October 15, 2009 announcing the completion

of Pfizer s acquisition of Wyeth.

Forward-Looking Statements

This Current Report on Form 8-K (including information included or

incorporated by reference herein) includes "forward-looking statements"

within the meaning of the safe harbor provisions of the United States

Private Securities Litigation Reform Act of 1995. Such statements may

include, but are not limited to, statements about the benefits of the

merger between Pfizer and Wyeth, including future financial and

operating results, the combined company's plans, objectives,

expectations and intentions and other statements that are not historical

facts. Such statements are based upon the current beliefs and

expectations of Pfizer's management and are subject to significant risks

and uncertainties. Actual results may differ from those set forth in the

forward-looking statements. Pfizer does not undertake any obligation to

update publicly or revise any forward-looking statements. The following

factors, among others, could cause actual results to differ from those

set forth in the forward-looking statements: the possibility that the

expected synergies from the merger of Pfizer and Wyeth will not be

realized, or will not be realized within the expected time period, due

to, among other things, the impact of pharmaceutical industry regulation

and pending legislation that could affect the pharmaceutical industry;

the risk that the businesses will not be integrated successfully;

disruption from the merger making it more difficult to maintain business

and operational relationships; Pfizer's ability to accurately predict

future market conditions; dependence on the effectiveness of Pfizer's

and Wyeth's patents and other protections for innovative products; the

risk of new and changing regulation and health policies in the U.S. and

internationally and the exposure to litigation and/or regulatory

actions. Additional factors that could cause results to differ

materially from those described in the forward-looking statements can be

found in Pfizer's 2008 Annual Report on Form 10-K filed with the

Securities and Exchange Commission (the "SEC") on February 27, 2009,

Wyeth's 2008 Annual Report on Form 10-K filed with the SEC on February

27, 2009, as amended on April 30, 2009, and Pfizer s Registration

Statement on Form S-4, which was declared effective by the SEC on June

17, 2009, included in the Risk Factors section of each of these

filings, and each company's other filings with the SEC available at the

SEC's Internet site (http://www.sec.gov).

Item

9.01 Financial Statements and Exhibits

(a) Financial Statements of Businesses Acquired

(1)

The audited consolidated balance sheets of Wyeth as of December 31,

2008 and December 31, 2007 and the consolidated statements of

operations, changes in stockholders equity and cash flows for each

of the three years in the period ended December 31, 2008, and the

notes related thereto, which were included in Wyeth s Annual Report

on Form 10-K for the fiscal year ended December 31, 2008 (filed on

February 27, 2009), are filed as Exhibit 99.2 and incorporated

herein by reference.

(2)

The unaudited consolidated condensed balance sheet of Wyeth as of

June 30, 2009 and the unaudited consolidated condensed statements of

operations, changes in stockholders equity and cash flows for the

six months ended June 30, 2009 and June 30, 2008, and the notes

related thereto, which were included in Wyeth s Quarterly Report on

Form 10-Q for the quarter ended June 30, 2009 (filed on August 6,

2009), are filed as Exhibit 99.3 and incorporated herein by

reference.

(b) Pro Forma Financial Information

(1)

The unaudited pro forma condensed combined financial statements of

Pfizer and Wyeth as of and for the six months ended June 28, 2009

and for the year ended December 31, 2008 are filed as Exhibit 99.4

hereto.

(d) Exhibits

Exhibits

Description

2.1

Agreement and Plan of Merger dated as of January 25, 2009, as

amended, among Pfizer Inc., Wagner Acquisition Corp. and Wyeth

(incorporated by reference to Exhibit 2.1 to Pfizer s Current

Report on Form 8-K, filed on January 29, 2009).

99.1

Press release of Pfizer Inc. dated October 15, 2009 announcing the

completion of the acquisition of Wyeth.

99.2

The audited consolidated balance sheets of Wyeth as of December 31,

2008 and December 31, 2007 and the consolidated statements of

operations, changes in stockholders equity and cash flows for each

of the three years in the period ended December 31, 2008, and the

notes related thereto (incorporated by reference to Exhibit 13 to

Wyeth s Annual Report on Form 10-K, filed on February 27, 2009).

99.3

The unaudited consolidated condensed balance sheet of Wyeth as of

June 30, 2009 and the unaudited consolidated condensed statements of

operations, changes in stockholders equity and cash flows for the

six months ended June 30, 2009 and June 30, 2008, and the notes

related thereto (incorporated by reference to Wyeth s Quarterly

Report on Form 10-Q for the quarter ended June 30, 2009, filed on

August 6, 2009).

99.4

Unaudited pro forma condensed combined financial statements of

Pfizer and Wyeth as of and for the six months ended June 28, 2009

and for the year ended December 31, 2008.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the

registrant has caused this report to be signed on its behalf by the

authorized undersigned.

PFIZER INC.

By:

/s/ Matthew Lepore

Matthew Lepore

Vice President, Chief Counsel Corporate Governance,

and Assistant General Counsel

Dated:

October 21, 2009

EXHIBIT INDEX

Exhibit No.

Description

2.1

Agreement and Plan of Merger dated as of January 25, 2009, as

amended, among Pfizer Inc., Wagner Acquisition Corp. and Wyeth

(incorporated by reference to Exhibit 2.1 to Pfizer s Current

Report on Form 8-K, filed on January 29, 2009).

99.1

Press release of Pfizer Inc. dated October 15, 2009 announcing the

completion of the acquisition of Wyeth.

99.2

The audited consolidated balance sheets of Wyeth as of December 31,

2008 and December 31, 2007 and the consolidated statements of

operations, changes in stockholders equity and cash flows for each

of the three years in the period ended December 31, 2008, and the

notes related thereto (incorporated by reference to Exhibit 13 to

Wyeth s Annual Report on Form 10-K, filed on February 27, 2009).

99.3

The unaudited consolidated condensed balance sheet of Wyeth as of

June 30, 2009 and the unaudited consolidated condensed statements of

operations, changes in stockholders equity and cash flows for the

six months ended June 30, 2009 and June 30, 2008, and the notes

related thereto (incorporated by reference to Wyeth s Quarterly

Report on Form 10-Q for the quarter ended June 30, 2009, filed on

August 6, 2009).

99.4

Unaudited pro forma condensed combined financial statements of

Pfizer and Wyeth as of and for the six months ended June 28, 2009

and for the year ended December 31, 2008.

-->